Wockhardt reports 51% EBITDA growth in FY26

Wockhardt Limited reported a financial performance for FY26 with an income of INR 3,373 Cr. and EBITDA of INR 630 Cr., representing a 51% year-over-year growth. The company disclosed these figures during an investor meeting held on June 4, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation highlighted the company's strategic focus on novel antibiotics, pharmaceuticals, and biotechnology, alongside a robust cash position of INR 662 Cr. and a net debt-to-equity ratio of 0.10 as of March 31, 2026.

Key Financials and Operational Performance

The investor presentation provided a detailed breakdown of Wockhardt's operational segments, showing significant regional contributions. The UK business achieved a 13% YoY growth driven by specialty injectables, while Ireland reported a 16% YoY growth in liquids and creams. Emerging Markets saw a 35% YoY growth, supported by strategic partnerships in Brazil, Thailand, Algeria, and Malaysia. The India business recorded an 8% YoY growth, led by an innovative portfolio including Emrok, Miqnaf, and Regenerative products.

Metric	FY26 Value
Income	INR 3,373 Cr.
EBITDA	INR 630 Cr.
Profit Before Tax	INR 238 Cr.
Cash & Cash Equivalents	INR 662 Cr.
Net Debt : Equity ratio	0.10

Strategic Growth Drivers

Management outlined a strategic roadmap focusing on the Zaynich global business, biotech acceleration, and a differentiated pharma R&D pipeline. A key highlight was the approval of Zaynich by the US FDA and CDSCO (India), positioning the company to address carbapenem-resistant infections. The company aims to enter 7-8 key markets with high CR burden in Latin America, Eurasia, GCC, and South/South East Asia within the next 18-24 months.

Future Outlook

Looking ahead, Wockhardt stated its objectives for the next two years include growth acceleration and sustainable operational excellence enabled by AI. The company emphasized its biosimilar diabetes franchise, with manufacturing infrastructure ready and a focus on human insulin and glargine, targeting a market size of approximately US$ 1.5 Billion. The pipeline includes assets such as Aspart, Degludec, and Semaglutide, targeting a market size of ~ US$ 5.6 Billion.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.17%	+4.57%	+27.40%	+38.90%	+14.55%	+287.85%

Wockhardt Limited announced on May 30, 2026, that it has received approval from the U.S. Food and Drug Administration (FDA) for ZAYNICH™ (cefepime and zidebactam). This novel intravenous antibiotic is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis. This approval marks a significant milestone as ZAYNICH™ is the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to receive FDA approval.

Clinical Efficacy and Trial Results

The FDA approval was based on the results of the Phase 3 ENHANCE-1 clinical trial. ZAYNICH™ demonstrated superior efficacy compared to meropenem, achieving a composite clinical cure and microbiological response rate of 89.0% versus 68.4% for meropenem. The treatment difference was 20.6% (95% CI; 12.3, 29.5). The randomized, double-blind, multicenter study enrolled 530 patients across 64 sites in the U.S., Europe, LATAM, China, and India. The drug was generally well tolerated during the study.

Parameter	Details
Drug Name	ZAYNICH™ (cefepime and zidebactam)
Indication	Complicated Urinary Tract Infections (cUTI)
Efficacy Rate	89.0%
Comparator	Meropenem (68.4% efficacy)
Trial Patients	530

Mechanism of Action and Designations

ZAYNICH™ is a multi-penicillin-binding protein targeting combination of the 4th generation cephalosporin cefepime and zidebactam. Unlike most other beta-lactam combinations, it targets multiple penicillin binding proteins (PBP 1a/b, 2 and 3) simultaneously. This mechanism provides bactericidal activity against challenging drug-resistant Gram-negative bacteria. The drug previously received Qualified Infectious Disease Product (QIDP), Fast Track, and Priority Review designations from the FDA.

Regulatory and Strategic Milestones

Dr. Habil F. Khorakiwala, Founder and Chairman of Wockhardt Group, highlighted that this approval represents a historic milestone for the Indian pharmaceutical industry. Prior to the U.S. approval, ZAYNICH™ was approved by the Drugs Controller General of India (DCGI) on May 27, 2026. Wockhardt has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency. The company currently has a pipeline of six antibiotics, all granted QIDP designation by the U.S. FDA.